Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mengjun Sui
Observed names:
Sui, Mengjun,
隋孟君
Institution:
First Affiliated Hospital of Xi'an Jiaotong University
Observed institutions:
Northwest University,
First Affiliated Hospital of Xi'an Jiaotong University,
First Hospital of Xi'an,
Lanzhou University,
Xi'an Jiaotong University
ORCID:
0009-0009-2188-0872
Observed ORCID:
0009-0009-2188-0872
OpenAlex ID:
A5006197045
Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment
2021
·
Simeng Wang
, Xinrui Zhou
, et al.
·
Journal of Nanobiotechnology
·
46
PDF
Advancing Cancer Immunotherapy through Engineering New PD-L1 Degraders: A Comprehensive Study from Small Molecules to PD-L1-Specific Peptide–Drug Conjugates
2024
·
Zekun Zeng
, Zhiwei Yang
, et al.
·
Journal of Medicinal Chemistry
·
19
A Cryophyte Transcription Factor, CbABF1, Confers Freezing, and Drought Tolerance in Tobacco
2019
·
Xiule Yue
, Guoyan Zhang
, et al.
·
Frontiers in Plant Science
·
19
PDF
Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways
2023
·
Hui Dang
, Mengjun Sui
, et al.
·
International Journal of Biological Macromolecules
·
17
Genome-wide CRISPR screening identifies PHF8 as an effective therapeutic target for KRAS- or BRAF-mutant colorectal cancers
2025
·
Zhao Liu
, Yiqi Li
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
16
Engineering PD-L1 targeted liposomal canagliflozin achieves multimodal synergistic cancer therapy
2024
·
Simeng Wang
, Mengjun Sui
, et al.
·
Chemical Engineering Journal
·
10
Harnessing transcription factor-driven ROS for synergistic multimodal lung cancer treatment
2024
·
Ye Zhou
, Simeng Wang
, et al.
·
Journal of Controlled Release
·
9
A tumor-responsive nanostrategy for reducing the risk of immunotherapy-related myocarditis
2024
·
Mengjun Sui
, Simeng Wang
, et al.
·
Chemical Engineering Journal
·
2
TET1 loss propels the development of hyperthyroidism by remodeling histone modifications of PAX8 promoter
2025
·
Hui Dang
, Yan Liu
, et al.
·
Experimental & Molecular Medicine
·
1
PDF
Silk Fibroin-zwitterionic Core–shell Hydrogel Microspheres Loaded with Curcumin Micelles for Synergistic Antifouling and Protection of Encapsulated Islets
2026
·
Zuhan Chen
, Mohan Lu
, et al.
·
Regenerative Biomaterials
PDF
Supplementary Table S4 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
Supplementary Table S3 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
Supplementary Figure S1 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
Supplementary Table S1 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
Supplementary Table S2 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
Supplementary Table S5 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
Supplementary Figure S1 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
PDF
Supplementary Table S1 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
PDF
Supplementary Table S4 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
PDF
Supplementary Table S3 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
PDF
Data from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
Supplementary Table S5 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
PDF
Supplementary Table S2 from ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2026
·
Mengjun Sui
, Qing Cai
, et al.
PDF
ACYP2 Induces Temozolomide Resistance in Glioblastoma by Promoting PARP1-Mediated DNA Damage Repair
2025
·
Mengjun Sui
, Qing Cai
, et al.
·
Molecular Cancer Research
Atovaquone-HSA Nano-drugs Enhance the Efficacy of PD-1 Blockade Immunotherapy by Improving Hypoxic Tumor Microenvironment
2021
·
Simeng Wang
, Xinrui Zhou
, et al.
·
Research Square
PDF
Show more works
View as search
Works count:
27
Citation count:
139
H-index:
7
I10-index:
6
Year
Topic
Type